Susquehanna International Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,011,400
| Closed | -$2.31M | – | 13316 |
|
|
2024
Q2 | $2.31M | Buy |
1,011,400
+971,000
| +2,403% | +$3.71M | ﹤0.01% | 4819 |
|
|
2024
Q1 | $175K | Sell |
40,400
-108,400
| -73% | -$378K | ﹤0.01% | 10750 |
|
|
2023
Q4 | $454K | Sell |
148,800
-115,800
| -44% | -$218K | ﹤0.01% | 8919 |
|
|
2023
Q3 | $381K | Buy |
264,600
+14,900
| +6% | +$28.8K | ﹤0.01% | 8845 |
|
|
2023
Q2 | $622K | Buy |
249,700
+229,400
| +1,130% | +$627K | ﹤0.01% | 7798 |
|
|
2023
Q1 | $54.4K | Sell |
20,300
-12,400
| -38% | -$59.6K | ﹤0.01% | 11667 |
|
|
2022
Q4 | $178K | Sell |
32,700
-25,000
| -43% | -$210K | ﹤0.01% | 10293 |
|
|
2022
Q3 | $721K | Buy |
57,700
+36,600
| +173% | +$418K | ﹤0.01% | 7492 |
|
|
2022
Q2 | $104K | Buy |
21,100
+4,700
| +29% | +$26K | ﹤0.01% | 11446 |
|
|
2022
Q1 | $125K | Buy |
+16,400
| New | +$156K | ﹤0.01% | 11741 |
|
|
2021
Q4 | – | Sell |
-22,500
| Closed | -$302K | – | 14102 |
|
|
2021
Q3 | $302K | Sell |
22,500
-46,200
| -67% | -$753K | ﹤0.01% | 10592 |
|
|
2021
Q2 | $1.51M | Sell |
68,700
-144,000
| -68% | -$3.2M | ﹤0.01% | 6628 |
|
|
2021
Q1 | $5.12M | Buy |
212,700
+199,100
| +1,464% | +$4.63M | ﹤0.01% | 3862 |
|
|
2020
Q4 | $245K | Buy |
+13,600
| New | +$203K | ﹤0.01% | 9689 |
|
|
2020
Q3 | – | Sell |
-9,000
| Closed | -$218K | – | 11289 |
|
|
2020
Q2 | $218K | Buy |
+9,000
| New | +$149K | ﹤0.01% | 8892 |
|
|
2020
Q1 | – | Sell |
-9,300
| Closed | -$246K | – | 11040 |
|
|
2019
Q4 | $246K | Sell |
9,300
-18,400
| -66% | -$430K | ﹤0.01% | 8392 |
|
|
2019
Q3 | $631K | Buy |
27,700
+15,100
| +120% | +$476K | ﹤0.01% | 6750 |
|
|
2019
Q2 | $386K | Buy |
12,600
+1,600
| +15% | +$33.7K | ﹤0.01% | 7806 |
|
|
2019
Q1 | $183K | Buy |
+11,000
| New | +$209K | ﹤0.01% | 7932 |
|
Susquehanna International Group's GTHX Position: Q2 2024 in Review
Susquehanna International Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 950,839 shares — an estimated $3.63M sold.
Susquehanna International Group first reported a position in GTHX in Q2 2019 and held it in 19 quarters. The position peaked at $4.81M in Q4 2023. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.
- Susquehanna International Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Susquehanna International Group sold 950,839 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.63M.
- Susquehanna International Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- Susquehanna International Group's G1 Therapeutics, Inc. Common Stock position peaked at $4.81M in Q4 2023.
- 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.